Supplementary Table 1: Search Strategy

Search Strategy (Pubmed)	
#1	((vortioxetine[Title/Abstract]) OR Lu AA21004[Title/Abstract]) OR Brintellix[Title/Abstract]
#2	((((anxiety[Title/Abstract]) OR anxiety disorder[Title/Abstract]) OR anxiety disorders[Title/Abstract]) OR mood disorder[Title/Abstract]) OR mood disorders[Title/Abstract]
#3	Search "Anxiety Disorders"[Mesh]
#4 (#2 OR #3)	("Anxiety Disorders"[Mesh]) OR (((((anxiety[Title/Abstract]) OR anxiety disorder[Title/Abstract]) OR anxiety disorders[Title/Abstract]) OR mood disorder[Title/Abstract]) OR mood disorders[Title/Abstract])
#5 (#1 OR #4)	((("Anxiety Disorders"[Mesh]) OR (((((anxiety[Title/Abstract/]) OR anxiety disorder[Title/Abstract]) OR anxiety disorders[Title/Abstract]) OR mood disorder[Title/Abstract]) OR mood disorders[Title/Abstract]))) AND (((vortioxetine[Title/Abstract]) OR Lu AA21004[Title/Abstract]) OR Brintellix[Title/Abstract])
#6	Filters: Clinical Trial; Randomized Controlled Trial



Supplementary Figure 1: Search flow for the trial identification and selection process.



Supplementary Figure 2: Summarized risks of bias for the included studies.



Supplementary Figure 3: Odds ratios (ORs) and 95% confidence intervals (CIs) of the selected studies and the pooled data, comparing the discontinuation rates for any reason, between the vortioxetine and placebo groups.

Notes: (A) 2.5-mg/day vortioxetine versus placebo, (B) 5-mg/day vortioxetine versus placebo, and (C) 10-mg/day vortioxetine versus placebo.



Supplementary Figure 4: Odds ratios (ORs) and 95% confidence intervals (CIs) of the selected studies and the pooled data, comparing the discontinuation rates due to adverse events (AEs), between vortioxetine and placebo groups.

Notes: (A) 2.5-mg/day vortioxetine versus placebo, (B) 5-mg/day vortioxetine versus placebo, and (C) 10-mg/day vortioxetine versus placebo.